Furthermore, the GLP-1R agonists were already proven safe in clinical treatment for diabetes and obesity, it is worthwhile to develop antagonists of GLP-1R for PNETs treatment. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.